Amino Acids

, Volume 41, Issue 4, pp 875–884 | Cite as

Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma

  • Gisle Berge
  • Daniela Elena Costea
  • Marianne Berg
  • Heidi Rasmussen
  • Ida Grotterød
  • Ragnhild A. Lothe
  • Gunhild M. Mælandsmo
  • Kjersti FlatmarkEmail author
Original Article


Nuclear localization of the metastasis-associated protein S100A4 has been shown to correlate with advanced disease stage in primary colorectal carcinomas (CRC), but nuclear function and its relevance for the metastatic capacity of tumor cells is still unclear. Among several nuclear interacting protein partners suggested for S100A4, the tumor suppressor protein p53 has attracted particular interest, and previous studies suggest direct and indirect modes of interaction between the two proteins. The present study was undertaken to assess coexpression and potential interaction in CRC. TP53 mutational status and S100A4 expression were investigated in a selected series of primary CRC specimens (n = 40) and cell lines (n = 17) using DNA sequencing, western blot, and double immunostaining. Additionally, S100A4 and p53 were experimentally up- and down-regulated in vitro to assess reciprocal effects. For the first time, S100A4 and p53 coexpression was demonstrated in individual CRC cells, with nuclear colocalization as a particularly interesting feature. In contrast to previous studies, no correlation was observed between TP53 mutational status and S100A4 expression, and no evidence was obtained to support reciprocal regulation between the two molecules in the HCT116 isogenic cell line model. In conclusion, S100A4 and p53 were shown to be colocalized in individual nuclei of CRC cells, and it might be speculated whether the proteins interact in this subcellular compartment.


Colorectal neoplasms S100A4 p53 TP53 Metastasis 



We would like to thank Dr. Bert Vogelstein for kindly making the isogenic HCT116 cell model and p53 constructs available to us, Sigurd Bø for providing the siRNA constructs and Gunnvor Øijordsbakken for excellent technical assistance. The present work was supported by postdoctoral grants to K.F. (Norwegian Research Council, Grant Number 160604/V50), G.B. (Norwegian Cancer Society, Grant Number C99026) and D.E.C (Norwegian Research Council, Grant Number 178601), and by a PhD grant to M.B. (Norwegian Cancer Society, RAL: Grant Number A95068) and project support from the Functional Genomics Program in the Norwegian Research Council (Grant Number 152004/S10).

Conflict of interest statement

The authors declare no conflict of interest.

Supplementary material

726_2010_514_MOESM1_ESM.doc (812 kb)
Supplementary material 1 (DOC 812 kb)


  1. Ambartsumian NS, Grigorian MS, Larsen IF, Karlstrom O, Sidenius N, Rygaard J, Georgiev G, Lukanidin E (1996) Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. Oncogene 13:1621–1630PubMedGoogle Scholar
  2. Andersen K, Nesland JM, Holm R, Florenes VA, Fodstad O, Maelandsmo GM (2004) Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol 17:990–997PubMedCrossRefGoogle Scholar
  3. Aylon Y, Oren M (2007) Living with p53, dying of p53. Cell 130:597–600PubMedCrossRefGoogle Scholar
  4. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915PubMedCrossRefGoogle Scholar
  5. Borresen-Dale AL, Lothe RA, Meling GI, Hainaut P, Rognum TO, Skovlund E (1998) TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. Clin Cancer Res 4:203–210PubMedGoogle Scholar
  6. Bronckart Y, Decaestecker C, Nagy N, Harper L, Schafer BW, Salmon I, Pochet R, Kiss R, Heizman CW (2001) Development and progression of malignancy in human colon tissues are correlated with expression of specific Ca(2+)-binding S100 proteins. Histol Histopathol 16:707–712PubMedGoogle Scholar
  7. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW et al (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMedCrossRefGoogle Scholar
  8. Chen H, Fernig DG, Rudland PS, Sparks A, Wilkinson MC, Barraclough R (2001) Binding to intracellular targets of the metastasis-inducing protein, S100A4 (p9Ka). Biochem Biophys Res Commun 286:1212–1217PubMedCrossRefGoogle Scholar
  9. Dahl C, Ralfkiaer U, Guldberg P (2006) Methods for detection of subtle mutations in cancer genomes. Crit Rev Oncog 12:41–74PubMedGoogle Scholar
  10. Daoud SS, Munson PJ, Reinhold W, Young L, Prabhu VV, Yu Q, LaRose J, Kohn KW, Weinstein JN et al (2003) Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study. Cancer Res 63:2782–2793PubMedGoogle Scholar
  11. Davies BR, Davies MP, Gibbs FE, Barraclough R, Rudland PS (1993) Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. Oncogene 8:999–1008PubMedGoogle Scholar
  12. Davies MP, Rudland PS, Robertson L, Parry EW, Jolicoeur P, Barraclough R (1996) Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours. Oncogene 13:1631–1637PubMedGoogle Scholar
  13. Donato R (2003) Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 60:540–551PubMedCrossRefGoogle Scholar
  14. Fernandez-Fernandez MR, Veprintsev DB, Fersht AR (2005) Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor. Proc Natl Acad Sci 102:4735–4740PubMedCrossRefGoogle Scholar
  15. Flatmark K, Pedersen KB, Nesland JM, Rasmussen H, Aamodt G, Mikalsen SO, Bjornland K, Fodstad O, Maelandsmo GM (2003) Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol 200:589–595PubMedCrossRefGoogle Scholar
  16. Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad O, Paus E (2004) Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol 25:31–40PubMedCrossRefGoogle Scholar
  17. Ford HL, Salim MM, Chakravarty R, Aluiddin V, Zain SB (1995) Expression of Mts1, a metastasis-associated gene, increases motility but not invasion of a nonmetastatic mouse mammary adenocarcinoma cell line. Oncogene 11:2067–2075PubMedGoogle Scholar
  18. Garrett SC, Varney KM, Weber DJ, Bresnick AR (2006) S100A4, a mediator of metastasis. J Biol Chem 281:677–680PubMedCrossRefGoogle Scholar
  19. Gongoll S, Peters G, Mengel M, Piso P, Klempnauer J, Kreipe H, von Wasielewski R (2002) Prognostic significance of calcium-binding protein S100A4 in colorectal cancer. Gastroenterology 123:1478–1484PubMedCrossRefGoogle Scholar
  20. Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, Cohn M, Ambartsumian N, Christensen A et al (2001) Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. J Biol Chem 276:22699–22708PubMedCrossRefGoogle Scholar
  21. Helfman DM, Kim EJ, Lukanidin E, Grigorian M (2005) The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92:1955–1958PubMedCrossRefGoogle Scholar
  22. Iacopetta B, Russo A, Bazan V, Dardanoni G, Gebbia N, Soussi T, Kerr D, Elsaleh H, Soong R et al (2006) Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann Oncol 17:842–847PubMedCrossRefGoogle Scholar
  23. Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331PubMedCrossRefGoogle Scholar
  24. Lin J, Blake M, Tang C, Zimmer D, Rustandi RR, Weber DJ, Carrier F (2001) Inhibition of p53 transcriptional activity by the S100B calcium-binding protein. J Biol Chem 276:35037–35041PubMedCrossRefGoogle Scholar
  25. Lin J, Yang Q, Yan Z, Markowitz J, Wilder PT, Carrier F, Weber DJ (2004) Inhibiting S100B restores p53 levels in primary malignant melanoma cancer cells. J Biol Chem 279:34071–34077PubMedCrossRefGoogle Scholar
  26. Maelandsmo GM, Hovig E, Skrede M, Engebraaten O, Florenes VA, Myklebost O, Grigorian M, Lukanidin E, Scanlon KJ et al (1996) Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozyme. Cancer Res 56:5490–5498PubMedGoogle Scholar
  27. Marenholz I, Heizmann CW, Fritz G (2004) S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun 322:1111–1122PubMedCrossRefGoogle Scholar
  28. Mueller A, Schafer BW, Ferrari S, Weibel M, Makek M, Hochli M, Heizmann CW (2005) The calcium-binding protein S100A2 interacts with p53 and modulates its transcriptional activity. J Biol Chem 280:29186–29193PubMedCrossRefGoogle Scholar
  29. Parker C, Lakshmi MS, Piura B, Sherbet GV (1994) Metastasis-associated mts1 gene expression correlates with increased p53 detection in the B16 murine melanoma. DNA Cell Biol 13:343–351PubMedCrossRefGoogle Scholar
  30. Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L, Barraclough R (2000) Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. Cancer Res 60:1595–1603PubMedGoogle Scholar
  31. Sherbet GV, Lakshmi MS (1998) S100A4 (MTS1) calcium binding protein in cancer growth, invasion and metastasis. Anticancer Res 18:2415–2421PubMedGoogle Scholar
  32. Sorlie T, Johnsen H, Vu P, Lind GE, Lothe R, Borresen-Dale AL (2005) Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. Methods Mol Biol 291:207–216PubMedGoogle Scholar
  33. Takenaga K, Nakamura Y, Sakiyama S (1997) Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells. Oncogene 14:331–337PubMedCrossRefGoogle Scholar
  34. Tan M, Heizmann CW, Guan K, Schafer BW, Sun Y (1999) Transcriptional activation of the human S100A2 promoter by wild-type p53. FEBS Lett 445:265–268PubMedCrossRefGoogle Scholar
  35. Teodoro JG, Evans SK, Green MR (2007) Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med 85:1175–1186PubMedCrossRefGoogle Scholar
  36. van Dieck J, Fernandez-Fernandez MR, Veprintsev DB, Fersht AR (2009) Modulation of the oligomerization state of p53 by differential binding of proteins of the S100 family to p53 monomers and tetramers. J Biol Chem 284:13804–13811PubMedCrossRefGoogle Scholar
  37. Walker DR, Bond JP, Tarone RE, Harris CC, Makalowski W, Boguski MS, Greenblatt MS (1999) Evolutionary conservation and somatic mutation hotspot maps of p53: correlation with p53 protein structural and functional features. Oncogene 18:211–218PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Gisle Berge
    • 1
  • Daniela Elena Costea
    • 2
  • Marianne Berg
    • 3
    • 4
  • Heidi Rasmussen
    • 1
  • Ida Grotterød
    • 1
  • Ragnhild A. Lothe
    • 3
    • 4
  • Gunhild M. Mælandsmo
    • 1
  • Kjersti Flatmark
    • 1
    Email author
  1. 1.Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium HospitalOslo University HospitalOsloNorway
  2. 2.Section of Pathology, The Gade InstituteUniversity of BergenBergenNorway
  3. 3.Department of Cancer Prevention, Institute for Cancer Research, The Norwegian Radium HospitalOslo University HospitalOsloNorway
  4. 4.Centre for Cancer BiomedicineUniversity of OsloOsloNorway

Personalised recommendations